Houlihan Lokey - Spring 2024 Pharma Services

Houlihan Lokey - Spring 2024 Pharma Services

Last month, the Healthcare Group at Houlihan Lokey published their Spring Pharma Services sector spotlight.

Amongst other things, the report provided a thorough assessment, with a US lens, of the current state of the sector, key trends, factors influencing the market and future development.

Here are my key takeaways from the report:

The sector

The spotlight shows the pharma services sector continues to grow, with outsourced services seen as an efficient way to maximise return on investment (ROI) when dealing with long and expensive development processes. Key drivers leading to the adoption of outsourced partners include:

·      Limited infrastructure and capabilities

·      Lack of knowledge / expertise

·      Reduce time to market

·      Need to reduce cost

Growth

Pharma services growth (CAGR) is outperforming other healthcare segments at 8.4%.

Pharma Services CAGR (%) by subsector

59% of the businesses in the space are PE owned, with 32% privately held and 9% public. As complexity around drug development continues, outsourcing will remain attractive and Houlihan Lokey believe we can expect to see continued investment and M&A in the space.

Macro tailwinds

The report shows there are strong macro factors at play driving healthcare demand, and with that, the volume and complexity of new drug development.

Globally we have an aging population, increased rates of chronic disease and climbing healthcare costs. In the US over 70% of adults have 2 or more chronic illnesses, which in general terms is consistent with the global rise of comorbidities. Life expectancy has also increased.

These factors show no sign of slowing and are supporting the continued demand for outsourced service providers who assist in the drug development and production process.

Complexity and Cost

Demand for increasingly complex drugs is continuing to grow. For small to mid-cap biotech firms, with great pressure on limited resources and cost, the outsourcing sector will play a vitally important role in their ultimate success.

As new generation molecules, advanced therapies, and modalities to tackle chronic and difficult-to-treat diseases increase, so complexity and cost will grow.

📈 Biologics, orphan drugs, mRNA therapeutics, and cell and gene therapies are forecasted to experience double-digit growth in the coming years.

✅ With greater complexity embedded throughout development and manufacturing, these processes are ripe for outsourcing.

💨 Expedited approval processes are becoming more prevalent, which require greater efficiency and expertise.

✅ Quicker approval processes are often more complex to navigate and need a level of technical input that outsourcing expertise can offer.

📉 Returns on R&D are declining.

✅ CROs, CDMOs, and commercialization organizations providing cost effective, efficient, and technically advanced outsourcing options are obvious route forward.

Summary

Houlihan Lokey’s report offers evidence to support sustained, durable tailwinds that will continue to drive long term demand for the outsourced services sector.

Sustained demand for innovative medical technologies and advanced therapies has created optimism across the Biotech funding environment. I will caveat this to say such optimism won’t be evidenced in the outsourcing space for 12-18 months yet.

Increasing investment in R&D will sustain demand for outsourcing partners, as will growing complexity in drug development.  And as novel drug approvals continue to grow, so will the need for manufacturing and supply chain capability to meet capacity and demand.

You can read the full report via the link in the comments, which also goes into more detail around M&A activity, but I hope my summary offers you a useful overview of how the report views the pharma services market.



Yasmine Johnson

Marketing & Operations | Fuelling growth for CDMOs, CROs, and Pharma Services 🌱

4mo

Insightful takeaways Andrew! 💡

Andrew Mears

CEO & Co-Founder | Fuelling growth for CDMOs, CROs, and Pharma Services 🌱

4mo

Download the full report here ⬇ https://hl.com/insights/pharma-services-sector-spotlight/

Like
Reply

To view or add a comment, sign in

More articles by Andrew Mears

  • Global Workplace report 2024

    Global Workplace report 2024

    This month, Gallup released the 2024 Global Workplace report. It highlights several critical issues and trends…

    2 Comments
  • The Exit Experience

    The Exit Experience

    Organisations pore over the importance of creating a stellar onboarding experience for new employees. And rightly so.

    15 Comments
  • Tips for setting and achieving New Year's Resolutions and Personal Goals

    Tips for setting and achieving New Year's Resolutions and Personal Goals

    Like many others, over the holidays I reflect on the year and take time to reset for the year ahead. With the right…

  • What does this mean for the Pharma services sector?

    What does this mean for the Pharma services sector?

    The adoption of Recruitment Process Outsourcing (RPO) is reserved for large organisations with huge hiring…

    1 Comment
  • Creating the talent formula

    Creating the talent formula

    We entered 2023 with talk of green shoots, but a lot of apprehension. We gallop towards the end of 2023 - despite some…

    4 Comments
  • From Pars to Pivots: A reflection on my first 2 years in business

    From Pars to Pivots: A reflection on my first 2 years in business

    I have compared starting and building a business to playing a round of golf every day. You have 16 holes of…

    2 Comments
  • Boston opens its doors to BIO 2023

    Boston opens its doors to BIO 2023

    The BIO International Convention landed in Boston last week, with 15,000 exhibitors and attendees from across the…

    9 Comments
  • Cutting through the headwinds....

    Cutting through the headwinds....

    January was awash with reviews of 2022, new year resolutions, not to mention doom and gloom predictions for 2023…

    3 Comments
  • 45 not out. A note to my younger self.

    45 not out. A note to my younger self.

    Yesterday I turned the tender age of 45. In my early 20’s I vividly remember looking at people I knew in their 40’s and…

    20 Comments
  • Needing a metaphorical hug.......

    Needing a metaphorical hug.......

    Lockdown 3.0 has been the worst.

    9 Comments

Insights from the community

Others also viewed

Explore topics